Literature DB >> 1677258

Multidrug resistance-associated antigens on drug-sensitive and -resistant human tumour cell lines.

S E Mirski1, S P Cole.   

Abstract

In this paper the biochemical properties of the antigens detected by six murine monoclonal antibodies (MAbs) are described. These MAbs react selectively with the multidrug-resistant small cell lung cancer (SCLC) cell line, H69AR, compared to its sensitive parent cell line, H69 (Mirski & Cole, 1989). Because H69AR cells do not overexpress P-glycoprotein, the antigens detected by these MAbs may be markers for non-P-glycoprotein-mediated mechanisms of resistance. We found that the 36 kDa protein precipitated by MAb 3.186 is phosphorylated and has a pI of approximately 6.7. The 55 kDa protein precipitated by MAb 3.50 is also phosphorylated and has a pI of approximately 5.7. Several observations suggest that MAbs 3.80, 3.177 and 3.187 recognise the same 47 kDa molecule and hence only MAb 3.187 was characterised further. This MAb precipitates an acidic protein which runs as a streak on isoelectric focusing gels. The 25 and 22.5 kDa cell surface proteins precipitated by MAb 2.54 both have a pI of approximately 7.6. Treatment of immunoprecipitates with glycosidase F indicated that none of the proteins detected by MAbs 2.54, 3.187, 3.50 and 3.186 have large N-linked carbohydrates. The peptide nature of the epitopes detected by MAbs 2.54 and 3.186 was unequivocally demonstrated by precipitation from in vitro translation products of H69AR RNA. The antigens detected by MAbs 3.50 and 3.187 were not detectable in immunoprecipitates of translation products but the epitopes are probably peptides because they were destroyed by boiling in sodium dodecyl sulphate. When the reaction of the MAbs with a panel of 15 paired drug-sensitive and -resistant cell lines was examined in a cell enzyme-linked immunosorbent assay, only a few resistance associated reactions were observed. Most of the reactions were either negative or not resistance-associated. When tested with three SCLC cell lines, MAb 3.187 reacted in a manner consistent with the relative resistance of the cell lines. Antigens that had similar electrophoretic mobility to those from H69AR cells were precipitated from extracts of five human cell lines of various tumour types. These data indicate that the cross-reactivities of the MAbs are due to antigens shared among the cell lines and not just the expression of common epitopes on different proteins. Resistance-associated proteins with the biochemical properties of the antigens described in this paper have not been reported previously and they remain potential markers for the as yet to be determined mechanisms of drug resistance in SCLC and other human malignancies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677258      PMCID: PMC1977290          DOI: 10.1038/bjc.1991.232

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Gene isolation by screening lambda gt11 libraries with antibodies.

Authors:  R C Mierendorf; C Percy; R A Young
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

2.  Reduced permeability in CHO cells as a mechanism of resistance to colchicine.

Authors:  V Ling; L H Thompson
Journal:  J Cell Physiol       Date:  1974-02       Impact factor: 6.384

3.  Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.

Authors:  M K Danks; C A Schmidt; M C Cirtain; D P Suttle; W T Beck
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

4.  Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

Authors:  T C Hamilton; M A Winker; K G Louie; G Batist; B C Behrens; T Tsuruo; K R Grotzinger; W M McKoy; R C Young; R F Ozols
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

5.  Oncogene amplification and chromosomal abnormalities in small cell lung cancer.

Authors:  J M Ibson; J J Waters; P R Twentyman; N M Bleehen; P H Rabbitts
Journal:  J Cell Biochem       Date:  1987-04       Impact factor: 4.429

6.  Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line.

Authors:  J G Zijlstra; E G de Vries; N H Mulder
Journal:  Cancer Res       Date:  1987-04-01       Impact factor: 12.701

7.  Long-term survival in small cell carcinoma of the lung.

Authors:  A Niiranen
Journal:  Eur J Cancer Clin Oncol       Date:  1988-04

8.  Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.

Authors:  A M Deffie; T Alam; C Seneviratne; S W Beenken; J K Batra; T C Shea; W D Henner; G J Goldenberg
Journal:  Cancer Res       Date:  1988-07-01       Impact factor: 12.701

9.  Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.

Authors:  W S Dalton; B G Durie; D S Alberts; J H Gerlach; A E Cress
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

10.  Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells.

Authors:  P R Twentyman; N E Fox; K A Wright; N M Bleehen
Journal:  Br J Cancer       Date:  1986-04       Impact factor: 7.640

View more
  3 in total

Review 1.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 2.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

3.  Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line.

Authors:  S P Cole; M J Pinkoski; G Bhardwaj; R G Deeley
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.